Alfentanil pharmacokinetics in cardiac surgical patients

• Published in: Anesthesia and analgesia Vol. 78; no. 2; pp. 231 - 239
• Main Authors: HUG, C. C, BURM, A. G. L, DE LANGE, S
• Format: Journal Article
• Language: English
• Published: Hagerstown, MD Lippincott 01-02-1994
• Subjects: Adult; Alfentanil - blood; Alfentanil - pharmacokinetics; Anesthetics. Neuromuscular blocking agents; Biological and medical sciences; Blood Proteins - metabolism; Coronary Artery Bypass; Coronary Disease - blood; Coronary Disease - metabolism; Female; Hemodilution; Heparin - pharmacology; Humans; Male; Medical sciences; Middle Aged; Neuropharmacology; Pharmacology. Drug treatments; Protamines - pharmacology; Heart; Human; Surgery; Cardiovascular disease; Opiates; Narcotic analgesic; Pharmacokinetics; Coronary heart disease
• ISSN: 0003-2999; 1526-7598
• DOI: 10.1213/00000539-199402000-00007

There is growing interest in early tracheal extubation and intensive care unit. (ICU) discharge of cardiac surgical patients. Among the opioids currently available, alfentanil seems to be particularly suited to these goals because of its pharmacokinetic and pharmacodynamic characteristics. However, the pharmacokinetics of alfentanil after cardiopulmonary bypass (CPB) have not been fully characterized. Eight patients undergoing coronary artery bypass grafting (CABG) with hypothermic CPB received alfentanil 125 micrograms/kg intravenously (IV) at the induction of anesthesia and again 5 h later after the completion of CPB. Arterial blood samples were analyzed for alfentanil (n = 8) and for plasma proteins (n = 3). Arterial blood samples were obtained from another six patients for measurements of the concentrations of plasma proteins at various stages of the perioperative period. Compared to the pre-CPB period as well as to patients not exposed to CPB, CABG patients after CPB exhibited an increased elimination half-time (t1/2 beta = 180 +/- 55 min SD), central distribution volume (Vc = 0.25 +/- 0.07 L/kg), and total volume of distribution (Vdss 0.63 +/- 0.08 L/kg; Vd area 0.92 +/- 0.23 L/kg) which reflected a 33%-50% decrease in alpha 1-acid glycoprotein, the principal plasma protein to which alfentanil is bound. There was no substantial change in the concentration of free alfentanil at the start of CPB. The clearance of total alfentanil was not affected significantly by CPB. We conclude: 1) Alfentanil pharmacokinetics in CABG patients before CPB are similar to those found in noncardiac surgical patients and volunteers.